Page 67 - Update on Management of Renal Cell Carcinoma

Phase 2 CABOSUN Study:

Overall and Progression-free Survival

Overall Survival: Trend in Favor PFS: Cabozantinib Significantly

of Cabozantinib Longer than Sunitinib

Median No. of Median No. of
OS Deaths PFS Events
1.0 Cabozantinib (N=79) 26.6 mo 43 1.0 Cabozantinib (N=79) 8.6 mo 43
Probability of OS 0.6 Probability of PFS 0.6
Sunitinib (N=78)
5.3 mo
Sunitinib (N=78)
47
49
21.2 mo
0.8
0.8
0.4
0.4
0.2

0.0 0.2
0.0
0 3 6 15 12 15 18 21 24 27 30 33 36 39 42 0 3 6 15 12 15 18 21 24 27 30
Time Since Randomisation (Months) Time Since Randomisation (Months)
No. at risk No. at risk
CABO 79 76 71 64 58 47 45 42 41 31 23 15 8 4 2 CABO 79 51 37 24 22 18 12 5 2 1 0 79 51 37 24
SUNI 78 69 61 53 50 46 42 36 29 24 17 12 6 3 0 SUNI 78 36 21 12 9 5 3 2 1 0 0 78 36 21 12

Key caveats about CABOSUN:

• Phase 2 trial: validation from a prospective phase 3 study required to be practice-changing

• Limited sample size, relies on investigator reports for PFS

CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival

67 Choueiri TK, et al. Eur J Cancer 2018; 94:115-25.